Clinical outcomes of MDS-Eos, MDS-Bas, and MDS−/− patients
| . | MDS-Eos, n = 36 . | MDS-Bas, n = 34 . | MDS−/−, n = 229 . | P . |
|---|---|---|---|---|
| No. of deaths | 27 (75%) | 27 (79%) | 147 (64%) | NS |
| Cause of death | NS | |||
| AML3-150 | 13 | 14 | 65 | |
| BMF | 12 | 11 | 61 | |
| TRM | 0 | 0 | 6 | |
| Others | 2 | 2 | 15 |
| . | MDS-Eos, n = 36 . | MDS-Bas, n = 34 . | MDS−/−, n = 229 . | P . |
|---|---|---|---|---|
| No. of deaths | 27 (75%) | 27 (79%) | 147 (64%) | NS |
| Cause of death | NS | |||
| AML3-150 | 13 | 14 | 65 | |
| BMF | 12 | 11 | 61 | |
| TRM | 0 | 0 | 6 | |
| Others | 2 | 2 | 15 |
BMF indicates bone marrow failure; and TRM, therapy-related mortality.
Evolution to AML was diagnosed when the bone marrow blast percentage exceeded 30%.